BioCentury
ARTICLE | Clinical News

BMS reports Phase I/IIa data for LAG3 mAb plus Opdivo in melanoma

June 1, 2017 8:58 PM UTC

In an abstract released ahead of the American Society of Clinical Oncology meeting in Chicago, Bristol-Myers Squibb Co. (NYSE:BMY) reported data from a cohort of 31 evaluable melanoma patients who progressed on or after anti-PD-1 or anti-PD-L1 therapy in a Phase I/IIa trial showing that 80 mg BMS-986016 plus Opdivo nivolumab every 2 weeks led to an objective response rate (ORR) of 16% and disease control rate (DCR) of 45%. The open-label, dose-escalation, international trial is evaluating BMS-986016 with and without Opdivo in about 360 patients with advanced solid tumors.

BMS-986016 is an IgG4 mAb targeting lymphocyte-activation gene 3 (LAG3; CD223)...